Byssinosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Byssinosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Byssinosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Byssinosis pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Byssinosis pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Byssinosis pathophysiology
CDC on Byssinosis pathophysiology
Byssinosis pathophysiology in the news
Blogs on Byssinosis pathophysiology
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Byssinosis pathophysiology

Pathophysiology

Pathologic Findings

Acute HP

There are noncaseating interstitial granulomas and mononuclear cell infiltration in a peribronchial distribution. Giant cells are prominent.

Subacute or intermittent HP

The noncaseating granulomas are more well formed. There is bronchiolitis with or without organizing pneumonia. Interstitial fibrosis is present.

Chronic HP

There is chronic interstitial inflammation and alveolar destruction (honeycombing). There is dense fibrosis. The pathologic findings of chronic HP that are often associated with a poorer prognosis include the following 3 patterns of fibrosis:

• Predominantly peripheral fibrosis: in a patchy pattern with architectural distortion and fibroblast foci similar to usual interstitial pneumonia (UIP)

• Homogeneous linear fibrosis: similar to fibrotic nonspecific interstitial pneumonia (NSIP)

• Irregular predominantly peribronchiolar fibrosis

Pathophysiology of Immune Response

Exposure results in the development of circulating immunoglobulin G antibodies that are specific for the offending antigen. This antibody that forms is called the precipitating antibody, and it reacts with the specific putative antigen to form a precipitant. Initially the disease process was thought to be immunecomplex-mediated. However, subsequent studies have demonstrated that cell-mediated immunity is more important.

In the acute phase, there is a local increase in neutrophils in the alveoli and small airways. This is followed by an influx of mononuclear cells which release proteolytic enzymes, prostaglandins, and leukotrienes.